Advertisement
Prescreening for clots also effective
Should lead to better treatment
High-risk and real-world patients responded
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Study explores atezolizumab for myelodysplastic syndrome
FDA approval may come in 2019
Lower toxicity than conventional chemo
Advertisement
Advertisement